Last reviewed · How we verify

Vincristine, Irinotecan, Temozolomide

Centre Oscar Lambret · Phase 2 active Small molecule

Vincristine, Irinotecan, Temozolomide is a Small molecule drug developed by Centre Oscar Lambret. It is currently in Phase 2 development. Also known as: Vincristine-Irinotecan-Temozolomide.

At a glance

Generic nameVincristine, Irinotecan, Temozolomide
Also known asVincristine-Irinotecan-Temozolomide
SponsorCentre Oscar Lambret
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vincristine, Irinotecan, Temozolomide

What is Vincristine, Irinotecan, Temozolomide?

Vincristine, Irinotecan, Temozolomide is a Small molecule drug developed by Centre Oscar Lambret.

Who makes Vincristine, Irinotecan, Temozolomide?

Vincristine, Irinotecan, Temozolomide is developed by Centre Oscar Lambret (see full Centre Oscar Lambret pipeline at /company/centre-oscar-lambret).

Is Vincristine, Irinotecan, Temozolomide also known as anything else?

Vincristine, Irinotecan, Temozolomide is also known as Vincristine-Irinotecan-Temozolomide.

What development phase is Vincristine, Irinotecan, Temozolomide in?

Vincristine, Irinotecan, Temozolomide is in Phase 2.

Related